Floatz logo

Venetoclax

PSA Progression

Roswell Park Cancer InstituteSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the PSA Progression cohort.

Asset / SponsorPhaseRating
Enzalutamide
Roswell Park Cancer Institute
Phase 2BB
Cyclophosphamide
Barbara Ann Karmanos Cancer Institute
Phase 2B
Carboplatin
University of Washington
Phase 2B
Epirubicin
Barbara Ann Karmanos Cancer Institute
Phase 2B
Psma-Hbed-Cc
Jonsson Comprehensive Cancer Center
Phase 2B

View all 20 →

Same molecule, other indications

Venetoclax is also rated in:

Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveDormant
BBB
Indicative ·
72 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
BB
Indicative ·
70 / 100
View asset →
myeloid neoplasmDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →